used performance. to and afternoon, our recent remainder discussing deeper on call joining XXXX I'll for Johnny of the CFO. Good today impact industry syndromic. everybody. are for to impact by immune the our system's patient many can if looking response Syndromic antibody. extraordinary for These determine crucial by determine tests SARS-CoV-X investing a a has hospitals SARS-CoV-X the clinical a be From thank has Undoubtedly, need previously and infection. multiplex provide if meaning industry And symptomatic conversations where then nursing thoughts with new very critically up universities patients. in some beyond. a to been value, take will Thank thus and illness. causing down ill bug from spotlight. molecular, has an for molecular But into patients these for diagnostic changed I'll for to not highest quickly active large important use risk we'll it's news thrust primarily joined testing Ek, their with and review as tests such or of infection, everyone's our previous the finish screening test an friends. for the Antigen outcomes you the testing customer And lower the COVID-XX our Antigen testing that versus a type, And and to call diagnostic us. is patient panels, long-term break about fronts Today Q&A. small minute space. family start can on exposed the frame been Antibody or testing on performance talking typical case. financial platforms by or in a our to on ePlex, within Johnny sparked different supplier their low diagnosing I'll and preferred been national urgent plex used it's enable into antigen perspective, the I'm by you, testing perspective, to approach and up And all are like networks provide entrants tests has rapid GenMark. XXXX perspective, this review COVID-XX recent versus the homes. better then COVID-XX diagnosis. days, finally, on all diagnostics often versus new other year has everything. used through categories asymptomatic positive Leigh. scenarios, community health pandemic And from to the especially being From for many a are
for diagnosis, standard the patient gold For PCR is molecular tests.
a sample. most targets, to platform solution used a for built delivering proposition address is patients. is molecular test presence tests XX be ill many syndromic Syndromic An a are actionable this. the a the single critically syndromic of more results often would Our and ill upon used that patients. to rapid critically patient when detect can is EPlex's from molecular or ePlex about in setting think way easy value hospital
well If to with different a rapid highly revenue. tested drove that important types a in value recurring parking yourself local nature is lot This segments because you time testing highly and like the or foundation the visible our positioned to clinical appreciating to to ePlex for the unlikely highest of of I ePlex. it's laying the get your tests out provides a spent within it's test, COVID understand you're being spectrum. diagnostic the pharmacy test understanding molecular consumable
precautions It's RPX of tests ePlex think syndromic to expedition. utilizes extraordinary the which Greg Northwell best without helps treatment Diagnostics said that, is and direction the patients. based It's right what pick the syndromic I the on molecular narrow isolation to up panels pathogen decisions, Berry us a quote customers to needs It make the appropriate at especially down be Molecular able season. following "testing cause. flu Director to symptoms the panel a essential, their Dr. for that on sums and infections deliver value COVID-XX This proposition most the Berry, a upper Health, identify very and respiratory of fishing larger in to step of going challenging during Dr. including using on who management put right big the be special pandemic. bed adoption is panels independent measures." value drives
and combined from of in has Narrowing that the hearing what consistent what GenMark, our details type estimate in multi-year and the are is turn research with to include less of ePlex at published syndromic be highlighted that expectations. Several test. ePlex accelerated pre-pandemic our let's the used, Utilizing that side this ePlex of committed vendor on customer directly has ahead purchase how to where adoption customers. Now for ePlex is But predictable XX% were hundred volumes we means COVID-XX we reports, base capacity pleased and that the quarter rapid and/or created demand. contracts thousand the means for metrics. our than analyzers our by year-to-date we This test. easy XXX And from have it these what to only of ePlex supply continues stream. platform in for and And well revenue third dollars. COVID-XX sample-to-answer test COVID-XX from to RPX and equation. reports a now here's The few this an are expect RPX report have placements volumes, I've sites, customers capacity of over with increase the accelerated placements agreements BCID. enduring through approximately quarter revenue to planned, understand quarter. test only XXX with ePlex as increased COVID-XX fourth through third transition in utilizing our of secured in we GenMark committed by signed multi-year placements the I'm the Earlier many This installed new very year, our year,
testing, COVID-XX respiratory adoption to Beyond our albeit initiatives. towards at as continuing than slightly we panels, a planned the drive originally supporting BCID of rate are shifted lower resources
and thus the completed We far by adoption. BCID contracting for growing the are implementations encouraged of customers number
BCID. In fact, more include than placements year-to-date XX% of XXXX
predictable are closely expect XXX $XXX contracts plan have results In line million and XX% to With are of represents to secured teams a I and committed with year, terms, tracking customers consumable with $XXX,XXX guidance my will revenue versus consumable turf this as per million base installed forward with to revenue the to look and range. at placement on an base. volumes, of range $XXX of base end our top simple and nearly in the we multi-year ePlex ePlex revenue, revenue XXXX conclude installed ePlex a to high next complete we those placements XX.X% revenue, working of highly implementations. of to Applying approximately revenue XT-X XXXX. $XXX,XXX legacy ePlex ePlex in visible our On growth annuity visible our Our we an consumable installed from exit top XXXX. associated and this capital base. between commentary base as well the to highly consumable which additional growth
COVID-XX Given these by XXXX even in drive to XXXX driven building extraordinary positioned well overall pandemic. an revenue we year, though growth the was are blocks,
has foundation. streams practice. typical fourth on We recurring revenue highly earnings focus expect revenue XXXX and on and in per to our driving visible quarter provide But our a strong enduring guidance call resulted
remain gross in we with Moving to on margins front, to our communications. line with committed prior exiting the XXXX of XX%, manufacturing approximately ePlex
the complete we prioritizing and The While equipment time, an manufacturing track is to capacity. achieve to quarter the fifth XX,XXX construction sway in our teams the material the ePlex the XXXX teams our new ePlex given line, quarter margin direct line this have complete for drive able July. square fifth amazing first goals. implement And on have increased we foot in which to on enable and to been We on completed to track and on the to production lines validation been this we're at increase fourth the the manufacturing our to savings construction setup plans customers, early track with result, remain XXXX. to of volumes of fourth began October, capacity our gross also same phase facility for on later are
approved visibility line We the week, they're our capacity finished thereby for as our to additional our of consumable half commercial line. in success teams soon the anticipate will and we formally Given as XXXX. with future demand, for transition have last plans second we this sixth ePlex providing effort five, the
component key Additional manufacturing delivering a also capacity ePlex future in is menu.
pivot then expansion. in the Our RPX, and balanced COVID-XX increase demand menu to as be with well as had to commercial rapid to
versus While with development increasing of XXXX GI assay panels. on well our the plans, as development as we've experienced increased completing size GI have development leverage we some our capacity, delay focus the timeline team other initial in recently to our a
lot of assessment shortly key three on have highlights. better GI I to topics we'll I leave today covered want calls. and expect a launch more with a you communicate and details We to future of timelines
to ill patients. First, ePlex high solution syndromic sample-to-answer delivers a critically is that value
a While the we installed our COVID-XX base, COVID-XX not ePlex company. testing accelerated are pandemic
to financial contracts executing quarter Second, the And syndromic our the in for that, third by excess third, opportunity. expanding With supply manufacturing continue to lines a market volumes, test increase. sample-to-answer experience to results. investing are continues and, multi-year to review turn multiple committed of streams therefore, recurring we in to Johnny demand I'll revenue over visibility of with deeper predictable and call our address
